Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label crossover study of LIB003 versus evolocumab in homozygous familial hypercholesterolemia
MOH_2020-02-10_008660Phase 3Not yet recruiting
- Sponsor
- LIB Therapeutics, LLC
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lerodalcibep and evolocumab in homozygous familial hypercholesterolemia (HoFH) (2 arms), sponsored by LIB Therapeutics, LLC. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
lerodalcibepevolocumab
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on MOH_2020-02-10_008660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-02-10_008660.